Scientia Vascular Receives Clearance for the Zoom Wire: Commences Immediate Launch

Scientia Vascular, a leading innovator in the field of neurovascular treatment technology, recently received FDA clearance for its Zoom WireTM 14 guidewire line of interventional guidewires, which are used to gain access during ischemic and hemorrhagic stroke and other challenging neurovascular and peripheral vascular procedures.

Zoom Wire incorporates Scientia Vascular’s proprietary microfabrication design, enabling a new level of performance for the support and delivery of devices within the brain and other parts of the body.

Scientia Vascular Founder and CEO John Lippert stated, “We are pleased to offer the Zoom Wire line of guidewire products at a time when clinicians are in need of more supportive guidewires to deliver therapeutic devices quickly in time-critical interventions. Scientia is launching the Zoom Wire products immediately to key customers who have been requesting this follow-on product to the Aristotle 14, 18, and 24 guidewire families.” Mr. Lippert added: “The Zoom Wire 14 is the first product in a complete Zoom access family of devices, including new guidewires and innovative aspiration and microcatheters, which the company plans for release in 2021.”

Microfabricated guidewire products comprise over 60% of the current US interventional guidewire market, as these are the preferred type of guidewires for procedures ranging from routine to the most complex faced by interventional physicians. Scientia Vascular’s micro-fabrication platform represents the next generation in terms of innovation and performance, and with its recent launch of the Aristotle 18 and Aristotle 24 guidewires, it has quickly become the platform of choice for ischemic stroke procedures.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”